arsenic has been researched along with Myelodysplastic Syndromes in 67 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.49) | 18.2507 |
| 2000's | 38 (56.72) | 29.6817 |
| 2010's | 22 (32.84) | 24.3611 |
| 2020's | 6 (8.96) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, X; Liu, R; Liu, Y; Yang, H; Zou, X | 1 |
| Hu, XM; Liu, WY; Ma, R; Ming, J; Xiao, HY; Xu, YG | 1 |
| Liu, JX; Lu, P; Sun, MQ; Zhang, JY; Zhang, M | 1 |
| Deng, Z; Fan, T; Feng, X; Hu, X; Huang, G; Liu, W; Ma, R; Tang, Y; Wang, H; Wang, M; Wang, Y; Xiao, H; Yan, X; Yokota, A; Zhao, P | 1 |
| Du, Y; Hu, XM; Li, L; Ma, R; Wang, DX; Wang, HZ; Xu, YG; Yang, XP; Zhou, QB | 1 |
| Guo, YC; Hu, Q; Lu, JH; Ren, JY; Xu, BX; Xu, M; Zeng, Q; Zhou, YM | 1 |
| Ferrari, M; Hu, Z; Nizzero, S; Ramirez, MR; Shen, H; Shi, C; Wu, X; Zhang, G; Zhou, J | 1 |
| Chen, CJ; Deng, ZY; Hu, XM; Liang, JB; Qin, JY; Wang, MJ; Zhao, P | 1 |
| Gao, F; Ma, R; Xu, YG; Yang, XH | 2 |
| Mehta, SV; Shukla, SN; Vora, HH | 1 |
| Hirano, T; Hu, XM; Onda, K; Song, MM; Tanaka, S; Tohyama, K; Toyoda, H; Yuan, B; Zhou, AX | 1 |
| Hirano, T; Hu, XM; Liu, F; Ma, R; Onda, K; Tanaka, S; Toyoda, H; Yuan, B | 1 |
| Guan, X; Liu, J; Lu, R; Ma, J; Shao, X; Shao, Z; Zhan, Z; Zhao, J | 1 |
| Jin, J; Qian, W; Tong, H; Wang, Y; Xu, W | 1 |
| Gao, F; Hu, XM; Ma, R; Tang, XD; Wang, HZ; Xu, S; Xu, YG; Yang, XH; Zhou, QB | 1 |
| Fan, J; Guo, K; Li, Y; Li, Z; Weng, G; Wu, J; Xia, P; Zeng, Y; Zheng, R | 1 |
| Cen, JN; Gao, HQ; Hua, HY; Sun, AN; Wu, LL | 1 |
| Schiffer, CA; Srinivasan, S | 1 |
| Cen, J; Chen, Z; Gu, M; Liu, D; Qi, X | 1 |
| Ma, R; Xu, S | 1 |
| Chen, BA; Shao, ZY; Tang, M; Xia, GH; Zhang, L; Zhu, HG | 1 |
| Gotlib, J; Greenberg, PL | 1 |
| Sekeres, MA | 3 |
| Gotlib, J; Oh, ST | 1 |
| Allen-Bard, S; Christos, PJ; Curcio, T; Feldman, EJ; Mathew, S; Provenzano, J; Ritchie, EK; Roboz, GJ; Samuel, M; Segovia, J | 1 |
| Advani, A; Afable, M; Chan, J; Englehaupt, R; Erba, HP; Kalaycio, ME; Maciejewski, JP; Seel, S; Sekeres, MA; Sobecks, R | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Gao, F; Hassan, A; Klco, JM; Procknow, E; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Aguayo, A; Armillas-Canseco, FM; Martínez-Baños, D | 1 |
| Hu, XM; Liu, F; Ma, R; Sun, SZ; Wang, HZ; Xu, S; Xu, YG; Yang, XH | 1 |
| Guo, L; Hou, J; Shi, H; Wei, W; Zhang, Y; Zhou, F | 1 |
| Cilloni, D; Galimberti, S; Gioia, D; Guerrini, F; Levis, A; Messa, E; Palumbo, GA; Petrini, I; Petrini, M; Salvi, F | 1 |
| Lin, M; Tong, H | 1 |
| Beran, M; DiPersio, J; Greenberg, P; List, A; Rosenfeld, CS; Slack, J; Vey, N | 1 |
| Chen, JL; Li, Q; Li, RS; Song, XZ; Xu, M | 1 |
| Cai, Z; Lin, MF; Tong, HY; Xiong, H | 1 |
| Vey, N | 1 |
| Alvi, MI; Buonamici, S; Candoni, A; Chaudary, NI; Galili, N; Gallegos, JA; Gezer, S; Imran, M; Li, D; Lisak, L; Mumtaz, M; Nucifora, G; Pervaiz, H; Raza, A; Reddy, P; Singer, J; Tahir, S; Venugopal, P | 1 |
| Baldus, C; Hofmann, WK; Thiel, E; Uharek, L | 1 |
| Deeg, HJ; Li, X; Pu, Q; Shen, WM; Tohyama, K | 1 |
| Giles, FJ; Jabbour, EJ | 1 |
| Fukumoto, JS; Greenberg, PL | 1 |
| Balk, RA; Hassaballa, HA; Lateef, OB; Silver, MR | 1 |
| Abbasi, N; Deeg, HJ; Kerbauy, DM; Lesnikov, V; Scott, B; Seal, S | 1 |
| Jin, J; Lin, MF; Qian, WB; Tong, HY; Xu, WL | 1 |
| Jin, J; Lu, J; Xu, WL | 1 |
| Ding, RS; Jiang, SH; Lu, W; Xu, RR; Yuan, HJ | 1 |
| Stone, RM | 1 |
| Bosly, A; Bowen, D; Burnett, A; Casadevall, N; Dennis, M; Dombret, H; Dreyfus, F; Fenaux, P; Feremans, W; Guerci, A; Legros, L; Ribrag, V; Vey, N | 1 |
| Douer, D; Hainsworth, JD; List, AF; Mason, J; Rizzieri, D; Saleh, M; Schiller, GJ; Slack, J | 1 |
| Jin, J; Liu, J; Ni, W; Qian, W; Xu, W | 1 |
| Avivi, I; Gesundheit, B; Ofran, Y; Or, R; Rowe, JM; Zuckerman, T | 1 |
| Jin, J; Lu, J | 1 |
| Cui, X; Liu, T; Meng, WT; Xi, YM; Ye, XS | 1 |
| Dai, CW; Pei, MF; Shen, JK; Xu, YX; Zhang, GS; Zheng, WL | 1 |
| Hu, XM; Xu, S; Xu, YG | 1 |
| Chiodino, C; Donelli, A; Panissidi, T; Roncaglia, R; Torelli, G | 1 |
| Bloomfield, CD; Slack, JL; Tallman, MS; Tricot, G; Waxman, S | 1 |
| Miller, WH | 1 |
| List, AF | 1 |
| Anwar, N; Arshad, A; Bukhari, S; Fatima, N; Shaheen, S; Shamsi, T | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Anderson, C; Conway, SR; Firshein, SI; Pastuszak, WT; Rezuke, WN | 1 |
17 review(s) available for arsenic and Myelodysplastic Syndromes
| Article | Year |
|---|---|
The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis.
Topics: Arsenic Trioxide; Arsenicals; Humans; Myelodysplastic Syndromes; Network Meta-Analysis; Oxides; Treatment Outcome | 2023 |
Oral Arsenic-Containing Qinghuang Powder: A Potential Drug for Myelodysplastic Syndromes.
Topics: Aged; Arsenic; Arsenicals; Drugs, Chinese Herbal; Humans; Myelodysplastic Syndromes; Powders | 2022 |
Realgar (α-As
Topics: Arsenicals; DNA; DNA Methylation; Humans; Myelodysplastic Syndromes; Sulfides | 2022 |
Current treatment options and strategies for myelodysplastic syndromes.
Topics: Age Factors; Antimetabolites, Antineoplastic; Arsenic Trioxide; Arsenicals; Blood Transfusion; Clinical Trials as Topic; Comorbidity; Disease Progression; Erythropoietin; Farnesyltranstransferase; Hematinics; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Myelodysplastic Syndromes; Oxides; Recombinant Proteins; Social Class; Stem Cell Transplantation | 2008 |
[Progress of arsenic trioxide in treating myelodysplastic syndromes].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Myelodysplastic Syndromes; Oxides | 2009 |
Novel biospecific agents for the treatment of myelodysplastic syndromes.
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; Etanercept; Farnesyltranstransferase; Humans; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Oxides; Receptors, Tumor Necrosis Factor; Thalidomide | 2003 |
Arsenic trioxide as a treatment for myelodysplastic syndrome.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; DNA-Binding Proteins; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; MDS1 and EVI1 Complex Locus Protein; Multicenter Studies as Topic; Myelodysplastic Syndromes; Oxides; Proto-Oncogenes; Salvage Therapy; Thalidomide; Transcription Factors | 2006 |
Antiangiogenesis in myelodysplastic syndrome.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Receptors, Vascular Endothelial Growth Factor; Thalidomide | 2011 |
Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Physiological Phenomena; Clinical Trials as Topic; Humans; Myelodysplastic Syndromes; Oxides; Treatment Outcome | 2003 |
Arsenic trioxide for the treatment of myelodysplastic syndromes.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase II as Topic; Humans; Myelodysplastic Syndromes; Oxides; Treatment Outcome | 2004 |
Arsenic trioxide as a treatment for myelodysplastic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Division; Clinical Trials as Topic; Dexamethasone; DNA-Binding Proteins; Drug Therapy, Combination; Glutathione; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; MDS1 and EVI1 Complex Locus Protein; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Proto-Oncogenes; Transcription Factors | 2005 |
New agents in myelodysplastic syndromes.
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Apoptosis; Arsenicals; Azacitidine; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Cytokines; DNA Methylation; Enzyme Inhibitors; Farnesyltranstransferase; Growth Substances; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Myelodysplastic Syndromes; Oligonucleotides, Antisense; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2005 |
Management of patients with higher risk myelodysplastic syndromes.
Topics: Age Factors; Antimetabolites, Antineoplastic; Arsenic Trioxide; Arsenicals; Azacitidine; Combined Modality Therapy; Disease-Free Survival; Farnesyltranstransferase; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Oxides; Prognosis; Risk Factors; Treatment Outcome | 2005 |
New data with arsenic trioxide in leukemias and myelodysplastic syndromes.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Oxides | 2007 |
Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tretinoin | 2002 |
Molecular targets of arsenic trioxide in malignant cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Glutathione; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides | 2002 |
New approaches to the treatment of myelodysplasia.
Topics: Amifostine; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Prognosis; Proto-Oncogene Mas; Risk Factors; Severity of Illness Index; Thalidomide; Topotecan; Treatment Outcome | 2002 |
11 trial(s) available for arsenic and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Association of Gene Mutations with Response to Arsenic-Containing Compound Qinghuang Powder () in Patients with Myelodysplastic Syndromes.
Topics: Adult; Arsenic; Arsenicals; Blood Transfusion; Drugs, Chinese Herbal; Female; Genetic Association Studies; Humans; Karyotype; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Treatment Outcome | 2019 |
[Effects of arsenic trioxide on Id4 methylation status in bone marrow mononuclear cells and its clinical efficacy for myelodysplastic syndrome].
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; DNA Methylation; Female; Humans; Inhibitor of Differentiation Proteins; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Treatment Outcome; Young Adult | 2014 |
Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Karyotyping; Male; Middle Aged; Myelodysplastic Syndromes; Nausea; Oxides; Risk Factors; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome | 2011 |
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Oxides; Salvage Therapy; Treatment Outcome | 2011 |
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Azacitidine; Bone Marrow; Bone Marrow Cells; Cohort Studies; Decitabine; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Young Adult | 2011 |
Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder.
Topics: Adolescent; Adult; Aged; Arsenicals; Chromosome Aberrations; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Treatment Outcome; Young Adult | 2011 |
A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Oxides; Pilot Projects; Survival Analysis; Thalidomide; Treatment Outcome | 2012 |
Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Prognosis; Prospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Prognosis; Prospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Risk Factors; Thalidomide; Treatment Outcome; Tretinoin | 2008 |
39 other study(ies) available for arsenic and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Arsenic Dispensing Powder Promotes Erythropoiesis in Myelodysplastic Syndromes via Downregulation of HIF1A and Upregulation of GATA Factors.
Topics: Animals; Arsenicals; Cell Line; Down-Regulation; Drugs, Chinese Herbal; Erythropoiesis; GATA Transcription Factors; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Myelodysplastic Syndromes; Powders; Retrospective Studies; Up-Regulation | 2021 |
Arsenic concentration in peripheral blood is correlated with efficacy of a Traditional Chinese Medicine regimen containing realgar for the treatment of myelodysplastic syndrome.
Topics: Arsenic; Arsenicals; Humans; Medicine, Chinese Traditional; Myelodysplastic Syndromes; Prospective Studies; Sulfides | 2021 |
Effects of arsenic disulfide on apoptosis, histone acetylation, toll like receptor 2 activation, and erythropoiesis in bone marrow mononuclear cells of myelodysplastic syndromes patients in vitro.
Topics: Acetylation; Apoptosis; Arsenicals; Bone Marrow Cells; Cells, Cultured; Erythropoiesis; GATA1 Transcription Factor; Histone Deacetylase 1; Histones; Humans; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Sulfides; Toll-Like Receptor 2 | 2017 |
Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Topics: Alendronate; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Bone and Bones; Bone Marrow Cells; Cell Survival; Cells, Cultured; Decitabine; Mice, Transgenic; Myelodysplastic Syndromes; Nanoparticles; Oxides; Phosphatidylethanolamines; Polyethylene Glycols; Tissue Distribution | 2017 |
[Effects of qinghuang power combined Chinese herbs for shen reinforcing and Pi strengthening on activated T cells of myelodysplastic syndrome patients].
Topics: Adult; Aged; Arsenicals; Drugs, Chinese Herbal; Female; Flow Cytometry; Humans; Lymphocyte Activation; Male; Middle Aged; Myelodysplastic Syndromes; Phytotherapy; T-Lymphocytes, Regulatory; Young Adult | 2013 |
Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.
Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Oxides; Prognosis; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tandem Repeat Sequences; Tretinoin; Young Adult | 2013 |
Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Cell Differentiation; Cell Proliferation; Erythroid Cells; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Sulfides | 2014 |
Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent myelodysplastic syndrome-progressed leukemia cell line F-36p with complex karyotype including monosomy 7.
Topics: Apoptosis; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cytokines; Humans; Karyotyping; Myelodysplastic Syndromes; Sulfides | 2014 |
[Effect of Qinghuang Powder combined Chinese herbs for Pi-strengthening and Shen-reinforcing on HIF-1alpha in bone marrow mononuclear cells of myelodysplastic syndrome patients: an experimental research].
Topics: Adolescent; Adult; Aged; Arsenicals; Bone Marrow; Bone Marrow Cells; Case-Control Studies; Drugs, Chinese Herbal; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Monocytes; Myelodysplastic Syndromes; Phytotherapy; Young Adult | 2014 |
Downregulation of hTERT: an important As2O3 induced mechanism of apoptosis in myelodysplastic syndrome.
Topics: Aged; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Blotting, Western; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Child, Preschool; Down-Regulation; Female; Humans; Myelodysplastic Syndromes; NF-kappa B; Oxides; Poly(ADP-ribose) Polymerases; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Sp1 Transcription Factor; Telomerase; Transcription Factor AP-1; X-Linked Inhibitor of Apoptosis Protein | 2014 |
[Effect of treatment for hypocellular myelodysplastic syndromes by a low dose qinghuang powder combined with Chinese drugs for Shen supplementing and Pi invigorating: a clinical observation].
Topics: Arsenicals; Drugs, Chinese Herbal; Hemoglobins; Humans; Medicine, Chinese Traditional; Myelodysplastic Syndromes; Neutrophils; Phytotherapy | 2014 |
Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Curcumin; Down-Regulation; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Leukemia; Myelodysplastic Syndromes; Oxides; Poly(ADP-ribose) Polymerases; RNA, Small Interfering; Stem Cells; Survivin | 2016 |
Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM‑1 human myelodysplastic syndrome cell line.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Drug Synergism; Epoxy Compounds; Gene Expression Regulation, Neoplastic; Humans; Myelodysplastic Syndromes; Oxides; Phenanthrenes; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species | 2016 |
Expression of Dlk1 gene in myelodysplastic syndrome determined by microarray, and its effects on leukemia cells.
Topics: Adult; Aged; Antigens, CD34; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium-Binding Proteins; Cell Cycle; Cell Proliferation; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Intercellular Signaling Peptides and Proteins; K562 Cells; Leukemia; Leukocytes, Mononuclear; Male; Membrane Proteins; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Oxides; Tetradecanoylphorbol Acetate; Up-Regulation | 2008 |
[Experimental study of effect of As2S3 nanoparticles on human MDS cell line (MUTZ-1)].
Topics: Apoptosis; Arsenicals; Caspase 3; Cell Cycle; Cell Line; Cell Proliferation; Humans; Myelodysplastic Syndromes; Nanoparticles | 2009 |
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Clinical Trials as Topic; Drug Approval; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Protein-Tyrosine Kinases; Thalidomide | 2008 |
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study.
Topics: Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Female; Gene Expression; Genes, bcl-2; Humans; Male; Myelodysplastic Syndromes; Oxides; Real-Time Polymerase Chain Reaction | 2012 |
[Arsenic trioxide induced p15INK4B gene expression in myelodysplastic syndrome cell line MUTZ-1].
Topics: Arsenic Trioxide; Arsenicals; Cell Line; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Gene Expression Regulation; Humans; Myelodysplastic Syndromes; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2002 |
[Analysis of caspases activity of hematopoietic progenitor cells and its significance in myelodysplastic syndromes].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase 9; Caspases; Hematopoietic Stem Cells; Humans; Myelodysplastic Syndromes; Oxides | 2003 |
[Inhibition effect of arsenic trioxide on the growth of human MDS cell line MUTZ-1 cells].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Division; DNA; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Myelodysplastic Syndromes; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger | 2004 |
Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Lineage; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; MDS1 and EVI1 Complex Locus Protein; Middle Aged; Myelodysplastic Syndromes; Oxides; Proto-Oncogenes; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Spleen; Thalidomide; Transcription Factors; Zinc Fingers | 2004 |
Nursing considerations for nontraditional treatment approaches to hematologic malignancies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Oxides; Treatment Outcome | 2004 |
Therapeutic spectrum in the treatment of myelodysplastic syndromes.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Erythropoietin; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Myelodysplastic Syndromes; Oxides; Transplantation, Autologous; Transplantation, Homologous | 2004 |
[Biologic changes in MDS-L cell line induced by As2O3 and/or TRAIL].
Topics: Antigens, CD34; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line; Cyclin-Dependent Kinase Inhibitor p15; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Immunohistochemistry; Myelodysplastic Syndromes; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; TNF-Related Apoptosis-Inducing Ligand | 2004 |
Acute lung injury induced by arsenic trioxide in a patient with refractory myelodysplastic syndrome.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Male; Myelodysplastic Syndromes; Oxides; Respiratory Distress Syndrome | 2005 |
NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Bone Marrow Cells; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Enzyme Activation; Etanercept; Flow Cytometry; Glutathione; Growth Inhibitors; Humans; Immunoglobulin G; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Myelodysplastic Syndromes; NF-kappa B; Oxides; Protein Transport; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
[Study on the mechanisms of telomerase regulations during apoptosis of the human MDS-RAEB cell line MUTZ-1 cells induced by arsenic trioxide].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Line; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression; Humans; Myelodysplastic Syndromes; Oxides; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Telomerase; Telomeric Repeat Binding Protein 2 | 2005 |
[Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Myelodysplastic Syndromes; Neoplasm Transplantation; Oxides; Random Allocation; Survival Rate; Thalidomide; Tumor Cells, Cultured | 2006 |
[Apoptosis of in vitro cultured BMMNC from MDS patients induced by arsenic sulfide].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Arsenicals; bcl-2-Associated X Protein; Bone Marrow Cells; Cyclin D1; Female; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Myelodysplastic Syndromes; RNA, Messenger; Sulfides | 2006 |
Is intravenous arsenic trioxide a useful therapy in myelodysplastic syndromes?
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Humans; Infusions, Intravenous; Myelodysplastic Syndromes; Oxides; Treatment Outcome | 2006 |
Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1.
Topics: Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Beclin-1; Cell Death; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, T-Cell; Membrane Proteins; Myelodysplastic Syndromes; Oxides; Phosphorylation; Proto-Oncogene Proteins c-akt; Structure-Activity Relationship; Up-Regulation | 2007 |
Differentiation syndrome with lethal lung injury after arsenic trioxide treatment for myelodysplastic syndrome.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Pulmonary Alveoli; Respiratory Distress Syndrome; Syndrome | 2007 |
[Mechanisms of arsenic trioxide induced tumor cell apoptosis in myelodysplastic syndrome mice model in vivo].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspases; Disease Models, Animal; Electrophoretic Mobility Shift Assay; Humans; I-kappa B Proteins; Immunohistochemistry; Mice; Mice, Nude; Mice, SCID; Mitochondria; Myelodysplastic Syndromes; NF-kappa B; NF-KappaB Inhibitor alpha; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide | 2006 |
[Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs].
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; Disease Progression; DNA Methylation; Genetic Predisposition to Disease; Humans; Leukemia; Myelodysplastic Syndromes; Oxides | 2007 |
[Effect of treatment for myelodysplastic syndrome by Qinghuang Powder combined with Chinese herbs for reinforcing shen and strenghening pi].
Topics: Adolescent; Adult; Aged; Anemia, Refractory; Arsenicals; Diagnosis, Differential; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Male; Medicine, Chinese Traditional; Middle Aged; Myelodysplastic Syndromes; Phytotherapy; Stanozolol; Treatment Outcome; Young Adult | 2008 |
Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cell Culture Techniques; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Inhibitors; Humans; Leukemia, Myeloid; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Oxides | 2000 |
Environmental and occupational determinants of myelodysplastic syndrome: A case-control study from Pakistan.
Topics: Arsenic; Benzene; Case-Control Studies; Humans; Myelodysplastic Syndromes; Pakistan; Powders; Water | 2022 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Arsenic intoxication presenting as a myelodysplastic syndrome: a case report.
Topics: Adult; Arsenic; Arsenic Poisoning; Bone Marrow; Diagnosis, Differential; Female; Humans; Myelodysplastic Syndromes; Pancytopenia; Poisoning | 1991 |